FLAGYL ER Drug Patent Profile
✉ Email this page to a colleague
When do Flagyl Er patents expire, and what generic alternatives are available?
Flagyl Er is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in FLAGYL ER is metronidazole. There are eighteen drug master file entries for this compound. Seventy suppliers are listed for this compound. Additional details are available on the metronidazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flagyl Er
A generic version of FLAGYL ER was approved as metronidazole by TEVA PHARMS USA on November 6th, 1984.
Summary for FLAGYL ER
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 172 |
Clinical Trials: | 74 |
Patent Applications: | 2,255 |
Formulation / Manufacturing: | see details |
DailyMed Link: | FLAGYL ER at DailyMed |
Recent Clinical Trials for FLAGYL ER
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Leiden University Medical Center | Phase 4 |
University of North Carolina, Chapel Hill | Phase 2 |
University of Amsterdam | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for FLAGYL ER
US Patents and Regulatory Information for FLAGYL ER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | FLAGYL ER | metronidazole | TABLET, EXTENDED RELEASE;ORAL | 020868-001 | Nov 26, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FLAGYL ER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pfizer | FLAGYL ER | metronidazole | TABLET, EXTENDED RELEASE;ORAL | 020868-001 | Nov 26, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FLAGYL ER
See the table below for patents covering FLAGYL ER around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 0744947 | COMPOSITIONS DE METRONIDAZOLE A LIBERATION MODIFIEE ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION (MODIFIED-RELEASE METRONIDAZOLE COMPOSITIONS AND METHODS FOR MAKING AND USING SAME) | ⤷ Try a Trial |
Japan | H09508381 | ⤷ Try a Trial | |
Brazil | 9506662 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLAGYL ER
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0328535 | 96C0021 | Belgium | ⤷ Try a Trial | PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |